BACKGROUND: Insulin resistance is a significant risk factor in the pathogenesis of type 2 diabetes. This article presents pilot study results of the dynamic insulin sensitivity and secretion test (DISST), a high-resolution, low-intensity test to diagnose insulin sensitivity (IS) and characterize pancreatic insulin secretion in response to a (small) glucose challenge. This pilot study examines the effect of glucose and insulin dose on the DISST, and tests its repeatability. METHODS:DISST tests were performed on 16 subjects randomly allocated to low (5 g glucose, 0.5 U insulin), medium (10 g glucose, 1 U insulin) and high dose (20 g glucose, 2 U insulin) protocols. Two or three tests were performed on each subject a few days apart. RESULTS: Average variability in IS between low and medium dose was 10.3% (p=.50) and between medium and high dose 6.0% (p=.87). Geometric mean variability between tests was 6.0% (multiplicative standard deviation (MSD) 4.9%). Geometric mean variability in first phase endogenous insulin response was 6.8% (MSD 2.2%). Results were most consistent in subjects with low IS. CONCLUSIONS: These findings suggest that DISST may be an easily performed dynamic test to quantify IS with high resolution, especially among those with reduced IS.
RCT Entities:
BACKGROUND:Insulin resistance is a significant risk factor in the pathogenesis of type 2 diabetes. This article presents pilot study results of the dynamic insulin sensitivity and secretion test (DISST), a high-resolution, low-intensity test to diagnose insulin sensitivity (IS) and characterize pancreatic insulin secretion in response to a (small) glucose challenge. This pilot study examines the effect of glucose and insulin dose on the DISST, and tests its repeatability. METHODS: DISST tests were performed on 16 subjects randomly allocated to low (5 g glucose, 0.5 U insulin), medium (10 g glucose, 1 U insulin) and high dose (20 g glucose, 2 U insulin) protocols. Two or three tests were performed on each subject a few days apart. RESULTS: Average variability in IS between low and medium dose was 10.3% (p=.50) and between medium and high dose 6.0% (p=.87). Geometric mean variability between tests was 6.0% (multiplicative standard deviation (MSD) 4.9%). Geometric mean variability in first phase endogenous insulin response was 6.8% (MSD 2.2%). Results were most consistent in subjects with low IS. CONCLUSIONS: These findings suggest that DISST may be an easily performed dynamic test to quantify IS with high resolution, especially among those with reduced IS.
Authors: Greet Van den Berghe; Alexander Wilmer; Greet Hermans; Wouter Meersseman; Pieter J Wouters; Ilse Milants; Eric Van Wijngaerden; Herman Bobbaers; Roger Bouillon Journal: N Engl J Med Date: 2006-02-02 Impact factor: 91.245
Authors: D J O'Gorman; H K R Karlsson; S McQuaid; O Yousif; Y Rahman; D Gasparro; S Glund; A V Chibalin; J R Zierath; J J Nolan Journal: Diabetologia Date: 2006-09-26 Impact factor: 10.122
Authors: Thomas F Lotz; J Geoffrey Chase; Kirsten A McAuley; Geoffrey M Shaw; Xing-Wei Wong; Jessica Lin; Aaron Lecompte; Christopher E Hann; Jim I Mann Journal: Comput Methods Programs Biomed Date: 2008-03 Impact factor: 5.428
Authors: Paul D Docherty; J Geoffrey Chase; Lisa Te Morenga; Thomas F Lotz; Juliet E Berkeley; Geoffrey M Shaw; Kirsten A McAuley; Jim I Mann Journal: J Diabetes Sci Technol Date: 2011-11-01
Authors: Erin J Mansell; Signe Schmidt; Paul D Docherty; Kirsten Nørgaard; John B Jørgensen; Henrik Madsen Journal: J Pharmacokinet Pharmacodyn Date: 2017-08-22 Impact factor: 2.745